| Introduction: Although bromocriptine has been approved as
an antidiabetic agent, few studies have reported the benefcial
effects of other anti-hyperglycemic long acting dopamine agonist
agents. In this regard, Cabergoline has fewer side-effects than
that of Bromocriptine which can be administered as one or two
days per week with higher compliance rates in patients.
Aim: To determine the effect of Cabergoline on glycaemic
control in patients with Type 2 Diabetes Mellitus (DM).
Materials and Methods: In this double-blind clinical trial,
initial laboratory parameters including Fasting Plasma Glucose
(FBS), 2 Hours Postprandial Plasma Glucose (2HPPG), HbA1c,
Total Cholesterol (T-Chol), Triglycerides (TG), and High Density
Lipoproteins (HDL) were assessed. The subjects were randomly
assigned into two case and control groups. The intervention
group received 0.25 mg Cabergoline tablets weekly for the frst
2 weeks and 0.5 mg per week for the next 12 weeks. Control
group also received placebo tablets. All clinical and laboratory
assessments were repeated 3 months after initial visit. Paired
t-test, independent t-test and chi-square were used for the
comparison of quantitative and qualitative variables, respectively.
Covariance analysis was also used to adjust for confounding
variables. p<0.05 was considered as statistically signifcant.
Results: HbA1c (p=0.01) and TG (0.04) levels were signifcantly
decreased after intervention in the case group compared to
the controls.
Conclusion: Cabergoline, over a 3 months period, exhibits
benefcial effects on HbA1C and TG levels and may possibly
be useful as a long-term anti-diabetic drug in patients with
type 2 DM. |